CA-XPRIZE
22.6.2021 18:26:04 CEST | Business Wire | Press release
XPRIZE , the global leader in designing and operating incentive competitions to solve humanity’s grand challenges, officially announced today the teams moving forward in the $10M XPRIZE Rainforest aimed at improving our understanding of the rainforest ecosystem.
Sponsored by Alana Foundation , the five-year XPRIZE Rainforest is a call-to-action to help save rainforests through the development of transformative, scalable, and affordable technology to autonomously survey and monitor biodiversity in real-time, leading to insights that communicate the health, well-being, and value of standing tropical rainforests. XPRIZE Rainforest is co-developing an inclusive framework throughout all stages of the competition that ensures competing teams co-design and co-create solutions with Indigenous Peoples and local communities as key stakeholders and not just beneficiaries.
These 33 teams will now leverage existing and emerging technologies, such as robotics, remote sensing, data analysis, artificial intelligence, and machine learning, to develop new rainforest biodiversity survey tools that deliver information more quickly and affordably, and in unprecedented detail.
“There has never been a more urgent time for our planet,” Peter Houlihan, Vice President of Biodiversity & Conservation at XPRIZE said. “These teams show great promise for developing exciting new approaches to enhance shared understandings of the planet’s most complex and biodiverse terrestrial ecosystems.”
All registered teams submitted a qualifying submission detailing their approach and proposed technologies. The judging panel selected 33 teams, which hail from more than 16 countries and bring a collection of diverse backgrounds and industry experience.
The XPRIZE Rainforest qualified teams are:
- ACT NOW - Amazonas Action Alliance, Ecuador
- AirWrx, Canada
- Alouatta, Mexico
- AraceEye, Canada
- BiodivExplorer, Switzerland
- BioSTREAM, United Kingdom
- Bioverse, Brazil
- Blue Devil Rainforest Divers, United States
- Brazilian Team, Brazil
- Dinizia Excelsa, Brazil
- FLOATING FAB, Peru
- GainForest, Switzerland
- Inspire Robotics, United States
- KAA Initiative, Brazil
- Kreativno pero, Serbia
- Lorax, United States
- Map of Life, United States
- Mimicry Maniacs, United States
- Mowgli, India
- Nga Kaitiaki o te Ngaherehere, New Zealand
- PROVIDENCE PLUS, Spain
- Rainforest Quest, United States
- Reforester, Netherlands
- Selvascope, Netherlands
- Short-Eared Dogs, United States
- Team Morpho, United States
- Team Robotics, Japan
- Team Waponi!, United States
- Tengo Research Foundation, Panama
- Treeswift (Trefos Inc), United States
- Welcome to the Jungle, United States
- XiniX AI, Belgium
- Zissou, Brazil
Additional details about all competing teams can be found here . Additionally, watch Peter Houlihan speak about XPRIZE Rainforest, performanced-based design and goal setting for impact on a World Rainforest Day event as part of the Rainforest Ambitions series. Register here .
In order to win the competition, the winning team will survey the most biodiversity contained in 100 hectares of tropical rainforest in 24 hours and produce the most impactful real time insights within 48 hours.
“Nature Based Solutions are key to confronting the climate crises. We are celebrating teams from the Americas, Europe, Oceania, and Asia all united on the same goal: protecting our standing forests that provide water, biodiversity, livelihood, and our prosperity with an inclusive bioeconomy. The joining of these teams shows the urgency we have to change the scenario we are living. The world needs intelligent, possible, powerful solutions, but above all, made by people in communion. We hope that Alana Rainforest XPRIZE will inspire activism, science, and innovation for the benefit of the environment and people all over the world,” said Ana Lúcia Villela, president of Alana Foundation.
Successful technologies developed in the competition will demonstrate scalable and affordable capabilities that measurably improve biodiversity monitoring, including through better autonomous operations, innovative detection methodologies, and rapid data integration to provide new Insights in real time and at unprecedented levels of detail.
The XPRIZE Rainforest Judging Panel consists of an experienced and talented group of experts working at the highest levels of academia, leading conservation organizations, prestigious research institutions and grantmaking organizations. The 9 judges include:
- Dr. Jorge Ahumada –– Senior Wildlife Conservation Scientist, Conservation International
- Dr. Luisa Arnedo –– Primatologist, Conservationist, and Senior Program Officer, National Geographic Society
- Dr. Stuart Davies –– Director, Center for Tropical Forest Science-Forest Global Earth Observatory at the Smithsonian Institution
- Dr. Lian Pin Koh –– Professor of Conservation, Science, Technology & Policy, Founder, Conservation Drones
- Dr. Lucia Lohmann –– Executive Director, Association for Tropical Biology and Conservation
- Dr. Kevin Njabo –– Associate Director & Africa Director, UCLA Center for Tropical Research and the Congo Basin Institute
- Dr. Vojtech Novotny –– Head, Dep. of Ecology, Biology Centre, Czech Academy of Sciences Director, New Guinea Binatang Research Center, Professor of Ecology, Zoology Dep., University of South Bohemia
- Atossa Soltani –– Founder & President of the Board, Amazon Watch; Director of Global Strategy for Amazon Sacred Headwaters Initiative
- Dr. Dave Thau –– Lead Scientist, World Wildlife Fund Global Data and Tech
The next step for the competition is the semifinal round and then a final round of testing before the grand prize decision in 2024. A total prize purse of $10 Million US dollars (USD) will be awarded throughout the lifespan of the prize, including a $250,0000 Bonus Prize that may be awarded at the Judging Panel’s discretion to one or more Finalist Teams whose Solutions demonstrate groundbreaking achievements. Milestone prizes will also be awarded equally for up to 25 teams that advance to Semifinals and up to 10 teams that advance to finals testing.
ABOUT XPRIZE
XPRIZE, a 501(c)(3) nonprofit organization, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $100M XPRIZE Carbon Removal, $15M XPRIZE Feed the Next Billion, $10 Million ANA Avatar XPRIZE and $5 Million XPRIZE Rapid Reskilling. For more information, visit xprize.org.
ABOUT ALANA FOUNDATION
Alana Foundation is an independent philanthropic organisation founded in 2012 in the United States. The Foundation supports initiatives in the areas of environment, inclusive education and health science research through grants and co-funding partnerships. It also engages with networks and global movements in those areas.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005926/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom